

Supplementary Table: Comparison of triple HF therapy versus no therapy in the HFREF cohort across the three hospitals

HF Medications- n (%)	Kolkata (India)		UHCW (UK) (n=480)	p-value		
	AGH (Private) (n=388)	NRS (Public) (n=216)		NRS - AGH	UHCW - AGH	UHCW - NRS
ACE inhibitor/ARB, beta-blocker and MRA	34 (8.8)	27 (12.5)	107 (22.2)	0.14	<0.001	0.002
No ACE inhibitor/ARB, beta-blocker and MRA	99 (25.5)	21 (9.7)	64 (13.3)	<0.001	<0.001	0.18

ACEi- angiotensin-converting enzyme inhibitor; ARB- angiotensin receptor blockade; MRA- mineralocorticoid receptor antagonist